Table 1 Demographic and clinical characteristics of study participants
Variables | N | % |
|---|---|---|
Age (years) (mean ± SD) | 41,1 ± 9,4 | |
Gender | ||
Male | 135 | 73,4 |
Female | 49 | 26,6 |
Baseline CD4 count, median (Q1; Q3) | 234, 0 (118, 0; 361, 0) | |
CD4 | ||
< 200 | 78 | 42,4 |
200 a 350 | 50 | 27,2 |
> 350 | 47 | 25,5 |
Data unavailable | 9 | 4,9 |
VL (copies/ml), median (Q1; Q3) | 19.812,5 (7.036,0; 78.674,2) | |
VL (copies/ml) | ||
≤ 10.000 | 59 | 32,1 |
> 10.000 a 100.000 | 75 | 40,7 |
> 100.000 | 37 | 20,1 |
Data unavailable | 13 | 7,1 |
∆t on ART (months), median (Q1;Q3) | 54, 5 (29, 0; 90, 0) | |
Δt in virologic failure (months), median (Q1;Q3) | 17, 0 (10, 0; 34, 0) | |
NRTI in failing regimen | 184 | 100,0 |
AZT/3TC | 126 | 68,5 |
TDF/3TC | 48 | 26,1 |
Others | 10 | 5,4 |
NNRTI in failing regimen | 155 | 84,2 |
EFV | 135 | 87,1 |
NVP | 20 | 12,9 |
PI in failing regimen | 29 | 15,8 |
LPV/r | 16 | 55,2 |
ATV/r ou ATV 400 mg | 12 | 41,4 |
Outros | 1 | 3,4 |
Viral Subtype | 171 | 92,9 |
B | 139 | 81,3 |
F | 31 | 18,1 |
BF | 1 | 0,4 |